<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581411</url>
  </required_header>
  <id_info>
    <org_study_id>CRVO-IAT1</org_study_id>
    <nct_id>NCT01581411</nct_id>
  </id_info>
  <brief_title>Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion</brief_title>
  <official_title>Phase 1 Trial of Intra-Ophthalmic Artery Thrombolysis for Treating Recent Severe Central Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <brief_summary>
    <textblock>
      1. Study hypothesis: Injection of t-PA, a thrombolytic drug (clot busting medicine)into the
           ophthalmic artery (the blood vessel feeding the eye), in patients with recent severe
           central retinal vein occlusion, may reopen the central retinal vein and improve retinal
           blood flow, which may in turn improve visual acuity and prevent the long-term
           complications of the disease.

        2. Experimental intervention: An outpatient procedure during which the ophthalmic artery is
           selective catheterized (with a small plastic tube called a microcatheter introduced from
           the artery of the leg) and infused with t-PA during two hours.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of retinal perfusion on the 1-week fluorescein angiogram, with no severe complications.</measure>
    <time_frame>One week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with 3 or more lines of visual acuity improvement during follow up.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Central Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>IA t-PA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra-ophthalmic artery injection of tissue plasminogen activator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue Plasminogen Activator</intervention_name>
    <description>Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours</description>
    <arm_group_label>IA t-PA</arm_group_label>
    <other_name>intra-arterial thrombolysis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe CRVO diagnosed on

               -  presence of relative afferent papillary defect (RAPD)

               -  or visual acuity of 20/200 or worse

          -  Symptom onset within 2 weeks

          -  Age &gt; 18 years old

          -  Patient is able and willing to give informed consent

        Exclusion Criteria:

          -  Futile intervention: no light perception, absence of perfusion on fluorescein
             angiography.

          -  Contra-indication to thrombolysis: active or recent (1 month) internal bleeding,
             cerebrovascular accident, major organ surgery, major trauma; intracranial neoplasm or
             vascular malformation, known bleeding diathesis, severe uncontrolled arterial
             hypertension, pregnancy (women of childbearing age must have a negative serum
             pregnancy test), or any other condition which in the opinion of the investigators
             would preclude the use of thrombolytic agents.

          -  High-risk catheterization: history of stroke or TIA; carotid bruit or known carotid
             occlusive disease; any cardiovascular condition that in the opinion of the
             investigators may increase the risk of catheterization of the ophthalmic artery.

          -  Ocular criteria: Intraocular neovascularization (secondary to any etiology), vitreous
             hemorrhage, inflammatory eye disease, any condition that precludes fundus photography
             or fluorescein angiography.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Y Pierre Gobin, MD</last_name>
    <phone>212 746 4998</phone>
    <email>yvg2001@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kimberly Salvaggio, NP</last_name>
    <phone>212 746 4998</phone>
    <email>kas2004@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medical College/ New York Presbyterian hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Y Pierre Gobin, MD</last_name>
      <phone>212-746-4998</phone>
      <email>yvg2001@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Salvaggio, NP</last_name>
      <phone>212 746 4998</phone>
      <email>kas2004@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Y Pierre Gobin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Szilard Kiss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Athos Patsalides, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donald D'Amico, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2012</study_first_submitted>
  <study_first_submitted_qc>April 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weill Medical College of Cornell University</investigator_affiliation>
    <investigator_full_name>Pierre Gobin</investigator_full_name>
    <investigator_title>Professor of Radiology in Neurosurgery and Neurology</investigator_title>
  </responsible_party>
  <keyword>central retinal vein occlusion</keyword>
  <keyword>macular edema</keyword>
  <keyword>vision loss</keyword>
  <keyword>rtelative afferent papillary defect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 27, 2016</submitted>
    <returned>June 6, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

